Tissue sections from patients’ prostate cancers (Gleason score 8–10) which had progressed to castration resistance following neo-adjuvant hormone therapy (n = 10) were stained and scored for BIRC6 expression and compared with sections of high grade prostate cancers (Gleason score 8–10) which had not been subjected to neo-adjuvant hormone therapy (n = 60). This evidence concerns the gene BIRC6 and prostate cancer.